Product Description
The research-grade biosimilar is a humanized IgG2 monoclonal antibody that specifically targets Sclerostin (SOST). Sclerostin is a glycoprotein secreted by the osteocytes during the remodeling of the bone. It binds to LRP5/6, a Wnt co-receptor, inhibits Wnt signaling pathway and bone formation. The antibody binds to and inhibits Sclerostin, thus releasing the inhibitory effect on Wnt signaling and enabling bone formation. The original antibody was approved by the FDA to treat postmenopausal women with osteoarthritis and patients that are at a high risk of fracture or have failed therapy for osteoporosis
Biovision | A2219 | Anti-SOST (Romosozumab), Humanized Antibody DataSheet
Antibody Target: SOST
Target Alternative Name: CDD, VBCH, DAND6, SOST1, Sclerostin, SOST, Sclerosteosis, AMG 785, CDP 7851, 785A070802
Tag Line: The biosimilar is a humanized monoclonal antibody that binds to and inhibits Sclerostin, thus activating WNT signaling pathway and promoting bone formation
Category: Biosimilars
Host: Recombinant
Isotype: IgG2, kappa
Species Reactivities: Human
Immunogen Sequence: Human SOST
Accession #: DB11866
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE